Published in Diabetes Care on July 01, 2005
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ (2009) 4.44
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ (2011) 4.05
PPARγ signaling and metabolism: the good, the bad and the future. Nat Med (2013) 3.71
Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol (2011) 2.16
The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol (2008) 1.81
Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) (2008) 1.64
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol (2014) 1.47
Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). Am J Cardiol (2009) 1.42
PPARs and the cardiovascular system. Antioxid Redox Signal (2009) 1.28
Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol (2007) 1.26
Diabetes, insulin, and development of acute lung injury. Crit Care Med (2009) 1.26
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care (2013) 1.22
Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf (2009) 1.18
A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf (2012) 1.17
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med (2011) 1.12
Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res (2008) 1.12
Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells. J Lipid Res (2010) 1.11
Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. Core Evid (2008) 1.06
Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol (2010) 1.06
PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res (2012) 1.04
PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) (2009) 1.03
A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V). J Diabetes Sci Technol (2014) 1.03
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord (2011) 1.01
PPAR-gamma in the Cardiovascular System. PPAR Res (2008) 1.01
Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab (2010) 1.01
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc Diabetol (2008) 0.99
Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig (2013) 0.98
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2009) 0.94
Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. PLoS One (2011) 0.92
Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag (2009) 0.91
Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies. PPAR Res (2008) 0.90
Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutr Metab (Lond) (2012) 0.90
Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes Metab (2009) 0.90
Effects of long-term pioglitazone treatment on peripheral and central markers of aging. PLoS One (2010) 0.90
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. J Diabetes Sci Technol (2009) 0.89
The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol (2011) 0.89
Identifying plausible adverse drug reactions using knowledge extracted from the literature. J Biomed Inform (2014) 0.89
Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response. Psychiatry Res (2015) 0.87
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes Care (2009) 0.87
The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis. J Am Heart Assoc (2013) 0.86
Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart (2006) 0.86
Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk. Vasc Health Risk Manag (2013) 0.86
Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. Vasc Health Risk Manag (2010) 0.83
Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice. PPAR Res (2014) 0.83
Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis (2012) 0.83
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Risk Manag (2007) 0.83
Topical peroxisome proliferator activated receptor activators accelerate postnatal stratum corneum acidification. J Invest Dermatol (2008) 0.83
Role of lipotoxicity in endothelial dysfunction. Heart Fail Clin (2012) 0.82
Andrographolide derivative AL-1 improves insulin resistance through down-regulation of NF-κB signalling pathway. Br J Pharmacol (2015) 0.82
Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes. Diabetes Care (2010) 0.82
PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system? World J Cardiol (2011) 0.82
Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2009) 0.82
Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile? Cardiovasc Diabetol (2016) 0.81
Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med (2014) 0.81
PPARγ activation redirects macrophage cholesterol from fecal excretion to adipose tissue uptake in mice via SR-BI. Biochem Pharmacol (2011) 0.81
Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes. Diabetes Metab Syndr Obes (2010) 0.81
Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Eff Resour Alloc (2009) 0.81
Should We Use PPAR Agonists to Reduce Cardiovascular Risk? PPAR Res (2008) 0.80
Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside. PPAR Res (2012) 0.80
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care (2013) 0.80
Clinical applications of advanced lipoprotein testing in diabetes mellitus. Clin Lipidol (2011) 0.80
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metab Res Rev (2012) 0.80
The Influences of Withdrawal and Daily Dose Reduction of Pioglitazone on Metabolic Parameters in Patients With Type 2 Diabetes: A Retrospective Longitudinal Observational Study. J Clin Med Res (2016) 0.80
Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial. Heart Vessels (2014) 0.79
Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab (2008) 0.79
Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects. Metabolism (2006) 0.79
Therapeutic Implications of PPARgamma in Cardiovascular Diseases. PPAR Res (2010) 0.79
Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial. Perit Dial Int (2012) 0.79
The management of type 2 diabetic patients with hypoglycemic agents. ISRN Endocrinol (2012) 0.79
Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J (2015) 0.78
Pioglitazone therapy in mouse offspring exposed to maternal obesity. Am J Obstet Gynecol (2013) 0.78
MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation. PPAR Res (2009) 0.78
Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus. Circulation (2014) 0.78
Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. Medicine (Baltimore) (2016) 0.78
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag (2010) 0.78
NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. Aliment Pharmacol Ther (2014) 0.77
Thiazolidinediones and cardiovascular risk - a question of balance. Curr Cardiol Rev (2009) 0.77
The effect of PPARalpha and PPARgamma ligands on inflammation and ABCA1 expression in cultured gallbladder epithelial cells. Dig Dis Sci (2008) 0.77
A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. Vasc Health Risk Manag (2007) 0.76
PPARγ signaling and emerging opportunities for improved therapeutics. Pharmacol Res (2016) 0.76
Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther (2011) 0.76
Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? PPAR Res (2009) 0.76
Are thiazolidinediones good or bad for the heart? Curr Diab Rep (2006) 0.76
Safety and efficacy of rosiglitazone in the elderly diabetic patient. Vasc Health Risk Manag (2009) 0.76
Glucose supply and insulin demand dynamics of antidiabetic agents. J Diabetes Sci Technol (2010) 0.76
Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis. J Diabetes Investig (2014) 0.76
In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist. PPAR Res (2012) 0.76
Drug vs class-specific black box warnings: does one bad drug spoil the bunch? J Gen Intern Med (2011) 0.75
Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. Cardiovasc Diabetol (2017) 0.75
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin. Diabetes Metab Syndr Obes (2010) 0.75
Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications. J Diabetes Investig (2012) 0.75
The sweet spot: continued search for the glycemic threshold for macrovascular disease-a retrospective single center experience. ISRN Cardiol (2012) 0.75
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al. Diabetes Care (2005) 0.75
Metabolic markers in Ossabaw pigs fed high fat diets enriched in regular or low α-linolenic acid soy oil. Nutr Metab (Lond) (2013) 0.75
Can the electrophysiological action of rosiglitazone explain its cardiac side effects? Curr Med Chem (2011) 0.75
PPARγ and Its Role in Cardiovascular Diseases. PPAR Res (2017) 0.75
Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL. J Lipid Res (2010) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care (2005) 3.93
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab (2013) 3.09
Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 2.96
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. J Diabetes Complications (2005) 2.64
Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem (2002) 2.61
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care (2009) 2.50
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003) 2.46
1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care (2006) 2.44
Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.15
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 2.11
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care (2012) 2.08
Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes (2013) 2.03
Assessment of group versus individual diabetes education: a randomized study. Diabetes Care (2002) 2.02
Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care (2007) 1.95
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
Consensus report of the coalition for clinical research-self-monitoring of blood glucose. J Diabetes Sci Technol (2008) 1.81
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
Prevention or delay of type 2 diabetes. Diabetes Care (2004) 1.73
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J (2013) 1.62
The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab (2011) 1.60
Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care (2002) 1.59
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals. Environ Health Perspect (2008) 1.53
A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care (2011) 1.47
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2007) 1.44
Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther (2007) 1.37
Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med (2010) 1.37
Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis (2002) 1.29
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab (2003) 1.26
Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther (2012) 1.26
Recruitment to a clinical trial improves glycemic control in patients with diabetes. Diabetes Care (2007) 1.23
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care (2012) 1.22
Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. Diabetes Care (2003) 1.16
Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med (2004) 1.13
Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab (2007) 1.12
Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care (2012) 1.11
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J (2008) 1.11
Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol (2002) 1.10
Maternally and zygotically provided Cdx2 have novel and critical roles for early development of the mouse embryo. Dev Biol (2010) 1.07
Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. Part Fibre Toxicol (2010) 1.07
Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care (2012) 1.06
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther (2006) 1.05
Impact of modem-transferred blood glucose data on clinician work efficiency and patient glycemic control. Diabetes Technol Ther (2005) 1.05
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care (2011) 1.04
Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin (2009) 1.04
Integrated tobacco cessation counseling in a diabetes self-management training program: a randomized trial of diabetes and reduction of tobacco. Diabetes Educ (2006) 1.03
Characterization of human brain nicotinamide 5'-mononucleotide adenylyltransferase-2 and expression in human pancreas. Biochem J (2004) 0.98
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res (2011) 0.98
North Carolina internists' and endocrinologists' knowledge, opinions, and behaviors regarding periodontal disease and diabetes: need and opportunity for interprofessional education. J Dent Educ (2011) 0.97
Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care (2013) 0.97
Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. Diabetes Care (2011) 0.96
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res (2006) 0.96
The prevention or delay of type 2 diabetes. Diabetes Care (2003) 0.95
Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: a preliminary study. J Clin Endocrinol Metab (2006) 0.93
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab Res Rev (2009) 0.93
Exploring salivary proteomes in edentulous patients with type 2 diabetes. Mol Biosyst (2012) 0.92
Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2013) 0.92
Development of progressive aortic vasculopathy in a rat model of aging. Am J Physiol Heart Circ Physiol (2007) 0.92
Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy. Cardiovasc Toxicol (2004) 0.91